Ginkgo Bioworks Director Releases Open-Source Go/No-Go Checklist for Biotherapeutic Teams

What Happened

Catherine Cifuentes-Rojas, a veteran in biotherapeutic development, has published a universal checklist designed to guide early-stage research programs. The tool aims to provide a structured framework for determining whether a project should proceed or be terminated.

The checklist consists of five fundamental questions that force teams to address potential flaws before committing further capital. It is intended to be used as a collaborative document at critical decision points to ensure data-driven, rather than personality-driven, outcomes.

By standardizing the evaluation process, the framework helps mitigate the influence of bias or seniority in laboratory settings. The resource is available to any discovery team, regardless of their specific therapeutic focus or corporate affiliation.

The Core Points

Five-question framework for evaluating early-stage biotherapeutic programs
Focuses on independent replication and rigorous stress-testing of hypotheses
Prioritizes in vivo data over early-stage in vitro indicators
Designed to be completed by cross-functional teams in under an hour
Removes subjective bias by requiring documented evidence for progression

Context in 60 Seconds

In the high-stakes environment of drug discovery, the pressure to maintain momentum often prevents teams from adequately testing the validity of their own hypotheses. This checklist addresses a persistent industry challenge: the difficulty of killing unsuccessful projects early, which often results in the misallocation of resources and time.

The move reflects a growing trend toward transparency and standardized rigor in biotech. By providing a neutral, evidence-based rubric, researchers can foster a culture where disconfirming data is viewed as a valuable asset rather than a project failure, ultimately protecting both institutional capital and scientific integrity.

Bottom Line

The new checklist offers a practical, evidence-based standard to help biotech teams objectively evaluate candidate viability and reduce the risks associated with early-stage drug development.

Loading briefing details...